Leukemia

Elderly patients with acute myeloid leukemia did not experience a difference in relapse-free survival or non-relapse mortality with intensive versus non-intensive chemotherapy.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

Varying outcomes among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia treated with pediatric-inspired protocols or adult chemotherapy regimens warrant further study.

"I’m on a healthy footing, and that’s pretty miraculous," said singer-songwriter Andrew McMahon, an acute lymphoblastic leukemia survivor and founder of the Dear Jack Foundation.

MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.

Why minimal residual disease testing is the "gold standard" for some patients and providers.

Here’s a look back at blood cancer approvals from the summer of 2023.

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, about the current research in treatments.

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, who discussed recent treatment advancements and FDA approvals.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

I had acute myeloid leukemia in 2016 and tackled it with chemo. I had a recurrence in 2020 and tackled it with chemo and a bone marrow transplant.

As wide receiver John Metchie returns to the field after cancer experience, and coach Brent Venables announces wife’s cancer diagnosis, this is what’s happening in the oncology space this week.

As Ben Alldis reveals previous cancer diagnosis and Luke Combs brings a Make-a-Wish cancer survivor on stage during a concert venue, this is what’s occurring in the oncology space this week.

The Food and Drug Administration approved a Vanflyta regimen for patients with FLT-ITD—positive acute myeloid leukemia.

A recent study has determined that Xospata plus chemo is safe for the treatment of relapsed/refractory acute myeloid leukemia with an FLT3 mutation.

Singer-songwriter Andrew McMahon is not the same person he was before his leukemia diagnosis, and that’s OK, he said.

There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.

Musician Andrew McMahon has made it his mission to spread the message of community and seeking mental health care like therapy for adolescents and young adults with cancer.

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Lasting guilt gets no one anywhere — especially when it comes to cancer.

The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.

Three-fourths of patients with relapsed/refractory B-cell acute lymphoblastic leukemia experienced complete responses — which tended to be durable — when treated with the CAR-T cell therapy, Obe-cel.